High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus

Journal of Internal Medicine

Volumn 270, Issue 4, 2011, Pages 309-318

  Urbonaviciute, V ^a   Voll, R E ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Autoantibodies; High mobility group box 1; Nucleosomes; Receptor for advanced glycation end products; Systemic lupus erythematosus; Toll like receptors

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AUTOANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE ACTIVATION; CELL ACTIVATION; COMPLEX FORMATION; CONFERENCE PAPER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DNA PROTEIN COMPLEX; HUMAN; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOLECULAR RECOGNITION; NONHUMAN; NUCLEOSOME; PATHOGENESIS; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; BIOLOGICAL MARKERS; HMGB1 PROTEIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MODELS, BIOLOGICAL; RECEPTORS, IMMUNOLOGIC;

EID: 80052975019     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02432.x     Document Type: Conference Paper

References (60)

1. Sessa L, Bianchi ME. The evolution of High Mobility Group Box (HMGB) chromatin in multicellular animals. Gene 2007; 387: 133-40.
2. Tsuda K, Kikuchi M, Mori K, Waga S, Yoshida M. Primary structure of non-histone protein HMG1 revealed by the nucleotide sequence. Biochemistry 1988; 27: 6159-63.
3. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999; 19: 5237-46.
4. Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta 2010; 1799: 101-13.
5. Calogero S, Grassi F, Aguzzi A et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 1999; 22: 276-80.
6. Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51.
7. Chen G, Li J, Ochani M et al. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leukoc Biol 2004; 76: 994-1001.
8. Jiang W, Pisetsky DS. The induction of HMGB1 release from RAW 264.7 cells by transfected DNA. Mol Immunol 2008; 45: 2038-44.
9. Gardella S, Andrei C, Ferrera D et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002; 3: 995-1001.
10. Andersson U, Tracey KJ. HMGB1 Is a Therapeutic Target for Sterile Inflammation and Infection. Annu Rev Immunol 2011; 29: 139-62.
11. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5.
12. Bell CW, Jiang W, Reich 3rd CF, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291: C1318-25.
13. Urbonaviciute V, Fürnrohr GB, Meister S et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes - implications for the immunopathogenesis of SLE. J Exp Med 2008; 205: 3007-18.
14. Abeyama K, Stern DM, Ito Y et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115: 1267-74.
15. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005; 17: 359-65.
16. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81: 1-5.
17. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-88.
18. Andersson U, Wang H, Palmblad K et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192: 565-70.
19. Rovere-Querini P, Capobianco A, Scaffidi P et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004; 5: 825-30.
20. Dumitriu IE, Baruah P, Valentinis B et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005; 174: 7506-15.
21. Tian J, Avalos AM, Mao SY et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8: 487-96.
22. Ivanov S, Dragoi AM, Wang X et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007; 110: 1970-81.
23. Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 2008; 180: 5067-74.
24. Hreggvidsdottir HS, Ostberg T, Wahamaa H et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 2009; 86: 655-62.
25. Castiblanco J, Varela DC, Castano-Rodriguez N, Rojas-Villarraga A, Hincapie ME, Anaya JM. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol 2008; 8: 541-4.
26. Yanai H, Ban T, Wang Z et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009; 462: 99-103.
27. Urbonaviciute V, Meister S, Furnrohr BG et al. Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis. Autoimmunity 2009; 42: 305-7.
28. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008; 29: 21-32.
29. Yang H, Hreggvidsdottir HS, Palmblad K et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 2010; 107: 11942-7.
30. Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009; 323: 1722-5.
31. Crispin JC, Liossis SN, Kis-Toth K et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010; 16: 47-57.
32. Popovic K, Ek M, Espinosa A et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum 2005; 52: 3639-45.
33. Barkauskaite V, Ek M, Popovic K, Harris HE, Wahren-Herlenius M, Nyberg F. Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus 2007; 16: 794-802.
34. Urbonaviciute V, Furnrohr BG, Weber C et al. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 2007; 81: 67-74.
35. Jiang W, Pisetsky DS. Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 727-8.
36. Li J, Xie H, Wen T, Liu H, Zhu W, Chen X. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 2010; 37: 766-75.
37. Park D, Tosello-Trampont AC, Elliott MR et al. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 2007; 450: 430-4.
38. Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: R71.
39. Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010; 6: 280-9.
40. Kruse K, Janko C, Urbonaviciute V et al. Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis 2010; 15: 1098-113.
41. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002; 2: 965-75.
42. Erwig LP, Henson PM. Clearance of apoptotic cells by phagocytes. Cell Death Differ 2008; 15: 243-50.
43. Liu G, Wang J, Park YJ et al. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol 2008; 181: 4240-6.
44. Friggeri A, Banerjee S, Biswas S et al. Participation of the receptor for advanced glycation end products in efferocytosis. J Immunol 2011; 186: 6191-8.
45. Friggeri A, Yang Y, Banerjee S, Park YJ, Liu G, Abraham E. HMGB1 inhibits macrophage activity in efferocytosis through binding to the alphavbeta3-integrin. Am J Physiol Cell Physiol 2010; 299: C1267-76.
46. Banerjee S, Friggeri A, Liu G, Abraham E. The C-terminal acidic tail is responsible for the inhibitory effects of HMGB1 on efferocytosis. J Leukoc Biol 2010; 88: 973-9.
47. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1241-50.
48. Baumann S, Krueger A, Kirchhoff S, Krammer PH. Regulation of T cell apoptosis during the immune response. Curr Mol Med 2002; 2: 257-72.
49. Baumann I, Kolowos W, Voll RE et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46: 191-201.
50. Ren Y, Savill J. Apoptosis: the importance of being eaten. Cell Death Differ 1998; 5: 563-8.
51. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008; 226: 10-8.
52. Garcia-Romo GS, Caielli S, Vega B et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011; 3: 73ra20.
53. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 2005; 38: 47-54.
54. Steinberg BE, Grinstein S. Unconventional roles of the NADPH oxidase: signaling, ion homeostasis, and cell death. Sci STKE 2007; 2007: pe11.
55. Brinkmann V, Reichard U, Goosmann C et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-5.
56. Qing X, Pitashny M, Thomas DB, Barrat FJ, Hogarth MP, Putterman C. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett 2008; 121: 61-73.
57. Ayer LM, Senecal JL, Martin L, Dixon GH, Fritzler MJ. Antibodies to high mobility group proteins in systemic sclerosis. J Rheumatol 1994; 21: 2071-5.
58. Rosenberg AM, Cordeiro DM. Relationship between sex and antibodies to high mobility group proteins 1 and 2 in juvenile idiopathic arthritis. J Rheumatol 2000; 27: 2489-93.
59. Sobajima J, Ozaki S, Uesugi H et al. Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC). Clin Exp Immunol 1998; 111: 402-7.
60. Hayashi A, Nagafuchi H, Ito I, Hirota K, Yoshida M, Ozaki S. Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod Rheumatol 2009; 19: 283-92.